Overview

The primary goal of this multi-faceted educational program is to improve the PCP’s ability to recognize the signs and symptoms of psoriatic disease, when to refer to specialty, and how to collaboratively advance patients along the correct treatment pathway in order to improve patient health outcomes.

Learning Objectives

  • Improve PCP knowledge and competence in the recognition & diagnosis of psoriasis and psoriatic arthritis, including a strong working knowledge of the various forms/ stages of psoriasis, and the common comorbidities, so as to better affect a timely referral and treatment with specialty. 
  • Improve PCPs clinical understanding of stage-appropriate pharmacological management of psoriasis and psoriatic arthritis so as to develop individualized treatment plans, which result in the greatest improvement in patient outcomes.
  • Assess the comparative risk-benefit profiles of available and emerging treatments for psoriasis, including topical, oral and biologic agents so as to better manage disease, while limiting unnecessary side effects and suboptimal outcomes.
  • Utilize clinician-patient communication strategies to clarify treatment expectations, emphasize the importance of adherence to therapy, and address patient concerns regarding the physical, psychological and emotional impact of psoriasis on QOL.

Courses

Disclosures

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Faculty Disclosures

Vasilios Chrisostomidis, DO

No relevant financial relationships to disclose. 

Sylvia Hsu, MD

Advisory Board for AbbVie, Inc.; Amgen; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Promius Pharma; Sun Pharma – Ranbaxy; and Valeant Pharmaceutical.

Anthony P. Fernandez, MD, PhD

Contracted Research for Mallinckrodt Pharmaceuticals, Roche Holding AG, and XOMA Limited. 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.


Commercial Supporter

Pfizer, Inc.

Education Partner

Vindico Medical Education


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC, or commercial supporters.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.